Financial anchor year: FY23. Margin and revenue are as filed for FY23. Balance-sheet measures (current ratio, equity financing, days in A/R) use FY20, the latest filing whose balance sheet reconciled as filed. Days cash on hand is FY22, the most recent year that passed the display gate. Every tile below states its own fiscal year; nothing is carried forward or estimated.
The read
A dialysis facility in GA. It ran an operating loss of 136.1% in FY23 on $0.5M of operating revenue. It held -1 day of cash on hand in FY22, its most recent reported liquidity — an Astrelis calculation outside expected range, shown at the chart boundary and ranked in its pool. 4 reporting years are on file, but revenue scale shifts too much between them for a like-for-like trend, so trend context is limited. These figures come from filings spanning FY20–FY23: read each by its own year rather than as one current picture.
Operating margin · FY23
-136.1%
Astrelis calculation · as-filed inputs
not ranked: no valid same-year pool for this metric (needs n ≥ 25 and ≥ 50% of the cohort's filers at FY23)
Days cash on hand · FY22
-1d
all sources
Astrelis calculation · as-filed inputs
not ranked: no valid same-year pool for this metric (needs n ≥ 25 and ≥ 50% of the cohort's filers at FY22)
Total operating revenue · FY23
$0.5M
Astrelis calculation · as-filed inputs
not ranked: no valid same-year pool for this metric (needs n ≥ 25 and ≥ 50% of the cohort's filers at FY23)
Total margin · incl. nonoperating · FY23
-136.1%
Astrelis calculation · as-filed inputs
not ranked: no valid same-year pool for this metric (needs n ≥ 25 and ≥ 50% of the cohort's filers at FY23)
The money
$ thousands · HCRIS cost-report basis · as filed, QA-gated
Ratios tell you how this dialysis facility is doing. Statements tell you what kind of organization it is, and where the money comes from. Every figure below traces to a public cost-report filing, shown as filed. A ratio computes only when every input is reported in the filing (otherwise its cell states which input is Not reported in source); a year whose balance sheet does not reconcile is labeled, and its derived ratios read Astrelis calculation unavailable. Not audited by Astrelis.
Operating margin
-136.1% (FY23)
Operating income ÷ total operating revenue
Astrelis calculation · HCRIS WS G-3
Total margin
-136.1% (FY23)
Net income ÷ total revenue incl. nonoperating
Astrelis calculation · HCRIS WS G-3
Days cash on hand
-1d (FY22)
Cash & investments ÷ daily operating expense
Astrelis calculation · HCRIS WS G / G-3
Current ratio
0.50× (FY20)
Total current assets ÷ current liabilities
Astrelis calculation · HCRIS WS G
Equity financing ratio
-53% (FY20)
Total net assets ÷ total assets
Astrelis calculation · HCRIS WS G
Days in net patient A/R
258d (FY20) — outside expected range; shown at the chart boundary and included in peer statistics
Net patient receivables ÷ (net patient revenue ÷ 365), same fiscal year
Astrelis calculation · HCRIS WS G / G-3
$ in thousands
Line item
FY21
FY22
FY23
Patient revenue
905
1,012
483
Total operating revenue
905
1,012
483
Total operating expenses
1,513
2,603
1,141
Operating income
(608)
(1,590)
(657)
Operating margin %
-67.2%
-157.1%
-136.1%
Other non-operating, net
0
6
0
Net income
(608)
(1,584)
(657)
Net income %
-67.2%
-155.4%
-136.1%
— = Not reported in source for that year.
HCRIS CMS-265 cost report · $ thousands · FY20–FY23 · operating revenue reflects net patient service revenue · FY20–21 may include COVID-era relief funding
Display states.FY23 · Operating margin: -136.1% — Astrelis calculation · outside expected range; shown at the chart boundary and included in peer statistics (beyond ±100%)FY23 · Total margin: -136.1% — Astrelis calculation · outside expected range; shown at the chart boundary and included in peer statistics (beyond ±100%)FY22 · Operating margin: -157.1% — Astrelis calculation · outside expected range; shown at the chart boundary and included in peer statistics (beyond ±100%)FY22 · Total margin: -155.4% — Astrelis calculation · outside expected range; shown at the chart boundary and included in peer statistics (beyond ±100%)FY20 · Operating margin: -387.7% — Astrelis calculation · outside expected range; shown at the chart boundary and included in peer statistics (beyond ±100%)FY20 · Total margin: -387.7% — Astrelis calculation · outside expected range; shown at the chart boundary and included in peer statistics (beyond ±100%)FY22 · Days cash on hand: -1 days — Astrelis calculation · outside expected range; shown at the chart boundary and included in peer statistics (outside the 0–1,500-day expected range — a valid filing can produce this; the pool absorbs it)
How it operates
quality & operational context · CMS public reporting
The metrics this dialysis facility type is judged on: care quality, patient experience, and scale. Each is labeled by provenance class and public source; descriptive context only, never a ranking or adequacy claim. Provenance labels: Reported value is copied from the named public source; Astrelis calculation is a formula applied to unchanged reported inputs, with the formula shown; Illustrative estimate is a benchmark gap, multiplier, or scenario — never a measurement.
Total treatments
1,746
Reported value2023
HCRIS CMS-265
Cost per treatment ($)
653.24
Astrelis calculation2023
HCRIS CMS-265
Net revenue per treatment ($)
276.67
Astrelis calculation2023
HCRIS CMS-265
Trajectory
Cost-report basis · 4 reporting years
Operating margin
Days cash on hand
State context
Georgia
County-level statistics: linkage not established— this record's county mapping is not verified in the resolved spine, and we never place a facility in a county by guesswork. State-level context appears here once a state aggregate layer lands.
A facility-specific dollar comparison cannot be calculated because a valid same-year peer pool was not reported. The report still includes all available facility measures, peer benchmarks, and a source-coverage inventory.
Report coverage: Limited Facility Benchmark. 7 of 10 facility measures available from public sources. The report covers the available measures against their peer benchmarks; measures the public record does not carry become findings. Coverage is disclosed here before you reserve, and thin data is never a decline reason. The refund guarantee stands: if we cannot deliver the published scope, you pay nothing.
The Board Briefing
Your facility and its world, board-ready. Measures the public record does not carry become findings, never a decline reason.
$1,000delivered within 2 business days of invoice
Reservation: invoice after coverage confirmation. No payment is collected on this site.
